Boulos, J.C.; Saeed, M.E.M.; Chatterjee, M.; Bülbül, Y.; Crudo, F.; Marko, D.; Munder, M.; Klauck, S.M.; Efferth, T.
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. Pharmaceuticals 2021, 14, 1126.
https://doi.org/10.3390/ph14111126
AMA Style
Boulos JC, Saeed MEM, Chatterjee M, Bülbül Y, Crudo F, Marko D, Munder M, Klauck SM, Efferth T.
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. Pharmaceuticals. 2021; 14(11):1126.
https://doi.org/10.3390/ph14111126
Chicago/Turabian Style
Boulos, Joelle C., Mohamed E. M. Saeed, Manik Chatterjee, Yagmur Bülbül, Francesco Crudo, Doris Marko, Markus Munder, Sabine M. Klauck, and Thomas Efferth.
2021. "Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells" Pharmaceuticals 14, no. 11: 1126.
https://doi.org/10.3390/ph14111126
APA Style
Boulos, J. C., Saeed, M. E. M., Chatterjee, M., Bülbül, Y., Crudo, F., Marko, D., Munder, M., Klauck, S. M., & Efferth, T.
(2021). Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. Pharmaceuticals, 14(11), 1126.
https://doi.org/10.3390/ph14111126